「镶边征」:一种诊断原发性中枢神经系统淋巴瘤的新影像标志物
本研究评估对比增强MRI上的「镶边征」能否鉴别原发性中枢神经系统淋巴瘤(PCNSL)与脑胶质瘤。测试集中该征象诊断PCNSL的敏感度为55.28%、特异度为91.93%;独立验证队列中阳性者85.09%为PCNSL,特异度90.40%。作者认为该征象是术前诊断PCNSL的高特异影像标志物,可能有助于临床诊疗。
要点
- 「镶边征」诊断PCNSL特异度高(测试集91.93%,验证队列90.40%),阳性者多为PCNSL。
- 出现「靶征」的肿瘤全部为PCNSL(16/16,100%),特异度与阳性预测值均为100%。
- 「镶边征」观察者间一致性高(κ=0.907),优于坏死/囊变及强化不均(κ=0.663-0.691)。
核心结论
- 对比增强MR上的「镶边征」观察者间一致性稳健,是术前诊断PCNSL的高特异影像标志物。
- 该无创标志物可能有助于指导PCNSL的临床诊断与治疗过程。
研究设计与样本
- 研究纳入161例PCNSL与161例胶质瘤的对比增强MR影像特征,由2名独立神经放射科医师评估。
- 评估内容包括「镶边征」有无、病灶坏死与囊变有无、肿瘤实质强化不均。
- 采用Cohen kappa(κ)评估观察者间一致性,并分析「镶边征」识别PCNSL的诊断效能。
- 另分析3个独立机构验证队列(含177例PCNSL与177例胶质瘤患者)以验证「镶边征」的诊断效能。
关键影像表现/征象
- 「镶边征」在89例(55.28%)淋巴瘤与13例(8.07%)胶质瘤病例中出现。
- 出现「靶征」的肿瘤全部为PCNSL(16/16,100%)。
诊断标准与关键数值
- 测试集中「镶边征」诊断PCNSL的敏感度55.28%、特异度91.93%、阳性预测值87.25%、阴性预测值67.27%。
- 「靶征」诊断PCNSL的特异度与阳性预测值均为100%(16/16,100%)。
- 验证队列中「镶边征」阳性者85.09%为PCNSL(p<0.0001),阳性预测值85.09%、阴性预测值66.67%、特异度90.40%、敏感度54.80%。
- 「镶边征」观察者间一致性κ=0.907,坏死/囊变及强化不均的κ=0.663-0.691。
临床应用与阅片要点
- 阅片时注意识别对比增强MR上的「镶边征」,其阳性对PCNSL具有高特异性。
- 「镶边征」敏感度约55%,阴性不能排除PCNSL。
- 出现「靶征」时高度提示PCNSL,原文报告该征象特异度与阳性预测值均为100%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate whether the "purfling sign," a new imaging marker, could distinguish primary central nervous system lymphoma (PCNSL) from brain gliomas, and its diagnosis value for preoperative identification of PCNSL.
METHODS: Contrast-enhanced MR imaging features of 161 PCNSL and 161 glioma were evaluated by 2 independent neuroradiologists: (1) the presence/absence of the "purfling sign"; (2) the presence/absence of lesion necrosis and cystic changes; and (3) the heterogeneity of tumor parenchymal enhancement. Inter-rater agreement was assessed with Cohen's kappa (κ), and the diagnostic performance of the "purfling sign" in identifying PCNSL was investigated. Three separate institutional validation cohort (including 177 PCNSL and 177 glioma patients) was analyzed to validate the diagnostic performance of the "purfling sign."
RESULTS: Among the test set, the inter-rater agreement of the "purfling sign" was high (κ = 0.907), while that for the other features was only good [κ = 0.663-0.691]. The purfling sign was present in 89 (55.28%) lymphoma and 13 (8.07%) glioma cases with a specificity of 91.93%, a sensitivity of 55.28%, a positive predictive value (PPV) of 87.25%, and a negative predictive value (NPV) of 67.27% for the diagnosis of PCNSL. Furthermore, the tumors presenting with the "target sign" were all PCNSL (16/16,100%), with a specificity and PPV of 100%. Analysis with the validation cohort, 85.09% cases with a positive "purfling sign" were PCNSL (p < 0.0001; PPV = 85.09%, NPV = 66.67%, specificity = 90.40%, sensitivity = 54.80%).
CONCLUSIONS: With a robust inter-rater agreement, our study found that the "purfling sign" on enhanced MR represents a high specific imaging marker for the preoperative diagnosis of PCNSL. This noninvasive marker may aid in the guidance of the clinical diagnosis and treatment processes of PCNSL.
引用
- Niu L, Zhao J, Duan C, et al. The "purfling sign": a new imaging marker for the diagnosis of primary CNS lymphoma. Radiol Med. 2025. PMID: 40350496. doi:10.1007/s11547-025-01970-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。